The Emergence of TYK2 Inhibitors in Psoriasis Treatment: A Synopsis

by

Key Takeaways: Psoriasis remains undertreated in the US due to factors such as concerns about side effects, monitoring requirements, and the use of injectable treatments. TYK2 inhibitors, like orally administered deucravacitinib, represent a promising new treatment option for psoriasis. Numerous hurdles, including treatment costs, specialist availability, insurance coverage, and safety concerns need addressing for effective… Read More

Understanding Mental Health as a Psoriasis Comorbidity

by

As common as Psoriasis is, the comorbidities associated with Psoriasis are often overlooked by patients and sometimes their physicians. As a part of their Psoriasis comorbidities series, Delaney Drew, and Kristi Hawley, DO have been publishing monthly articles to better identify, understand, and associate these issues. In part 2 published in October, mental health comes… Read More

Research shows link between Zinc Deficiency and Eczema

by

Zinc deficiency has been linked to eczema in ongoing research. While zinc creams and appointments may help soothe skin and reduce itching, they are not a first-choice treatment option for atopic dermatitis. If confirmed through continued research, it would provide a much-needed treatment option for one of the most common skin issues impacting patients around… Read More

The US FDA announces the approval of Dupilumab

by

The US Food and Drug Administration recently announced the approval of dupilumab, a fully human monoclonal antibody that inhibits the signaling of the IL-4 and IL-13 pathways while not suppressing the immune system. It’s the first and only treatment indicated for adults with prurigo nodularis (PN). It has been indicated for atopic dermatitis, asthma, nasal… Read More

Maintaining Remission of Rosacea Through Dermatologist and Patient Partnerships

by

While rosacea is treatable, its complex manifestations require consistent monitoring and treatment adjustments to achieve clear skin. Coordination between the physician and patient is critical to properly identify symptoms and apply the necessary changes throughout the therapy. This extended process often encounters issues when patients fail to express dissatisfaction and stop complying with their assigned… Read More

Promising signs from Novan’s Berdazimer Gel in Phase 3 Trials

by

In Phase 3 of B-SIMPLE 4’s clinical study published in JAMA Dermatology, Novan’s Berdazimer Gel outperformed the placebo significantly in the treatment of Molluscum. If approved, Berdazimer Gel would become the first prescription medication for the virus. Learn more about this development and explore more details about the study in the publication linked below. Novan’s… Read More

Are you using clean skincare products?

by

In the world of skincare, the term “clean” is often used to describe products free from harmful ingredients. However, there is no regulatory definition for “clean,” which can create confusion among consumers and skincare professionals. In a recent survey, one in four dermatologists admitted that they don’t know enough about clean skincare to make recommendations,… Read More

AbbVie Presents New Data Analyses for Growing Dermatology Portfolio

by

AbbVie announced it will present 27 abstracts across its dermatology portfolio, including new analyses evaluating the safety and efficacy of RINVOQ® in atopic dermatitis and new data on SKYRIZI® in psoriasis and psoriatic arthritis, at the 30th European Academy of Dermatology and Venereology (EADV) Congress, to be held virtually on September 29-October 2. Learn more